Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...
Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...
Abbott Laboratories: Strong Buy Rating Driven by Robust Growth Prospects and Operational Improvements
Bernstein analyst Lee Hambright maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...
Crain's Chicago Business2d
Abbott Labs board OKs $7 billion stock buyback program
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
A Glimpse of Abbott Laboratories's Earnings Potential
Abbott Laboratories ABT will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for ...
Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...